5 results about "Cell junction" patented technology

Provided herein are novel signal peptides that direct encoded proteins to cell junctions, recombinant polypeptides comprising the signal peptides, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.

The application discloses a kind of high efficiency gentle mammal blastocyst single cell dissociation method.The method includes the following steps: (1) zona pellucida removal: the blastocyst is placed in calcium magnesium table type liquid, and zona pellucida is completely removed by dissolving and physical blowing operation;(2) enzyme digestion incubation: the blastocyst after step (1) is handled and is transferred to 35-37 ℃ pre-equilibrated complex dissociation solution and incubated for 15-30 minutes, during which intermittent blowing is carried out, until the blastocyst is completely dissociated into single cell;(3) washing: the single cell obtained by dissociation is washed using dPBS, and the residual dissociation solution is removed.The method of the application has high efficiency, high activity and simplified operation.The dissociation process is simplified from 3-4 steps to two steps (zona pellucida dissolution+enzyme digestion incubation), the total time is shortened from more than 90 minutes to less than 30 minutes, the dissociation efficiency is significantly improved;Cell viability is increased from about 70% to more than 90%, the cell junction is gently lysed, and cell damage is reduced.

In particular, compositions comprising iPSC-derived parietal cell precursors (iMPCs) generated using NK3 homeobox 1 (NKX3.1; parietal cell fate-determining transcription factor) and methods for their preparation and use are described herein. In addition, in particular, methods for maturing iMPCs into functional parietal cell subtypes, including smooth muscle cells, perivascular cells, and fibroblasts, as well as methods for increasing angiogenesis, angiogenesis, and cell junctions, are described herein. iMPCs mediate the formation of functional blood vessels when transplanted together with endothelial cells (ECs); thus, methods for modeling vascular diseases (e.g., 3D vascular organoids (VOs)) and therapeutic vascularization, comprising a method of administering iMPCs and ECs and a step of administering iMPCs and ECs, are also described herein.

The application discloses a kind of peptide functionalized cellulose derivatives targeting A beta and its preparation method and application, belong to the field of biological medicine technology.The peptide functionalized cellulose derivative obtained by connecting A beta targeting peptide with hydroxypropyl cellulose through ester bond can be combined with A beta protein through molecular recognition specificity, and self-assembly is formed into core-shell structure nanomicelle, A beta oligomer is efficiently encapsulated, A beta aggregation and fiberization are inhibited, meanwhile, the interaction between A beta and endothelial cell junction protein is blocked by anti-fouling performance, APEL effect induced by amyloid is inhibited, and the integrity of blood-brain barrier is protected.In addition, the peptide functionalized cellulose derivative has good biocompatibility, can reduce A beta plaque deposition in brain, improve the cognitive function of AD patients, and provides a new type of efficient candidate drug for the treatment of Alzheimer's disease.

Provided herein are novel recombinant polypeptides comprising an endogenous cell junction targeting signal peptide and a payload protein, nucleic acid molecules encoding the recombinant polypeptides, pharmaceutical compositions comprising the nucleic acid molecules, and methods of use thereof.